The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe rheumatoid arthritis The primary objective for this study is to assess the efficacy of ABP 501 compared with adalimumab.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates To determine the effectiveness of AMG 162 in reducing urinary N-telopeptide (uNTx) below 50 nM BCE / mM creatinine in advanced cancer subjects with bone metastases (including multiple myeloma subjects...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 50 response at week 12.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease To describe histomorphometric parameters of bone turnover in dialysis subjects with high turnover renal osteodystrophy during treatment with Sensipar®/Mimpara® with or without concomitant vitamin D st...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates To evaluate the change in total hip Bone Mineral Density (BMD) at 12 months in postmenopausal women transitioning from previous daily or weekly bisphosphonate therapy to denosumab 60 mg SC Q6M compare...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis The primary objective is to determine whether denosumab (formerly known as AMG 162) treatment can reduce the number of postmenopausal osteoporotic women (BMD T-score below -2.5) with new vertebral fra...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Expanded Access Study of Talimogene Laherparepvec of Subjects in Europe with late stage Melanoma To provide access of talimogene laherparepvec for subjects with unresected stage IIIB to IVM1c melanoma in select countries in Europe until marketing authorization approval by the European Commission ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to evaluate evolocumab in people with type 2 diabetes mellitus with high cholesterol (hypercholesterolemia or mixed dyslipidemia). Estudio para evaluar evolocumab en sujetos con diabetes mellitus tipo 2 con colesterol alto (hipercolesterolemia o dislipidemia mixta) To evaluate the effect, the safety and tolerability of 12 weeks of subcutaneous (SC) evolocumab monthly (QM) compared with placebo QM on percent change from baseline in low-density lipoprotein cholest...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The purpose of this study is to find out more about the efficacy and safety of denosumab produced by two different processes in postmenopausal women with osteoporosis The primary objectives of this study are to evaluate 1. whether the efficacy of denosumab (60 mg subcutaneously every 6 months) manufactured by the proposed process referred to as CP4 is not inferio...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidism Demonstrate that treatment with AMG 416 is not inferior to treatment with cinacalcet for lowering plasma intact parathyroid hormone (PTH) levels by > 30% from baseline among subjects with chronic kidn...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune